Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab with TPF Induction and Chemoradiation in Head and Neck Cancer
NCT00646659Phase 2Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Feb 2008
- Primary completion
- May 2010
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cetuximab in squamous cell carcinoma of the head and neck (HNSCC) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Feasibility of the chemoradiotherapy part of the treatment. Started Feb 2008; status: terminated.
02
Drugs
cetuximab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00646659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00646659.